OKYO PHARMA LTD (OKYO)
GG00BMFG5F62 - Common Stock
OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma Announces Chairman Acquires Shares
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma CEO Interview to Air on Bloomberg TV
OKYO Pharma CEO Interview to Air on Bloomberg TV
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND...
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints...
OKYO Pharma Announces Participation in May 2024 Investor Conferences
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
Redx to Quit London Stock Exchange’s AIM, Citing Low Liquidity
Biotech company Redx Pharma Plc is set to pull its shares from the London Stock Exchange’s smallest market, citing liquidity constraints and saying it will attract investors more easily as a private company.
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain...
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024...
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...